# Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer

> **NCT04906044** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 46 (actual)

## Conditions studied

- Tislelizumab
- Locally Advanced Rectal Cancer
- Total Neoadjuvant Treatment
- PD-1

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04906044
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-01
- **Primary completion:** 2023-10-18
- **Final completion:** 2026-06-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906044, "Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04906044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*